Search clinical trials for: Tapentadol (CG5503) ER

Total 790 results

Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Compare the Dose-proportionality of Tapentadol (CG5503) in Healthy Japanese and Korean Male Volunteers

Healthy Volunteer
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Compare the Bioequivalence of 50-mg Tapentadol (CG5503) Dose Administered as Two 25-mg Tablets Relative to One 50-mg Tablet

Healthy Volunteer
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

Study on the Safety and Effectiveness of Switching Between Two Forms of Tapentadol in Patients With Chronic Low Back Pain

Low Back Pain
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Compare the Bioequivalence of 50-mg Tapentadol (CG5503) Dose Administered as Two 50-mg Tablets Relative to One 100-mg Tablet

Healthy Volunteer
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease

Arthritis | Joint Diseases | Osteoarthritis
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain

Pain | Lower Back Pain | Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Canada
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain

Low Back Pain
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain

Pain | Osteoarthritis | Low Back Pain

United States, Australia, Canada, New Zealand
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pivotal Study to Evaluate the Bio-equivalence of the Tapentadol Extended-Release (ER) Tamper-resistant Formulation (TRF) Tablet to the Current Tapentadol ER Prolonged-release 2 (PR2) Tablet

Healthy

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess Bioequivalence of a New Tapentadol Extended-Release 250-mg Tablet With Respect to a Tapentadol Extended-Release 250-mg Tablet in Healthy Participants

Healthy

United States
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

A Study to Evaluate the Effectiveness and Safety of Multiple Doses of Tapentadol(CG5503) in Patients Awaiting Joint Replacement Surgery

Osteoarthritis | Arthralgia | Pain Assessment
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.

Pain | Arthralgia | Bunion | Hallux Valgus

United States
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

Tapentadol (CG5503)

Pain | Osteoarthritis, Knee
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain From Bunionectomy Compared With Placebo Followed by a Voluntary Open Label Extension for Safety.

Arthralgia | Bunion | Hallux Valgus | Pain Assessment | Tapentadol
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Terminated

A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety

Arthroplasty

United States, United Kingdom, Belgium, Spain, Canada, Finland, New Zealand, Sweden
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess Bioequivalence of a New Tapentadol Extended-Release Tablet With Respect to a Tapentadol Extended Release Tablet Under Fasted Conditions in Healthy Subjects

Healthy

United States
Janssen Research & Development, LLC

Completed

A Safety and Efficacy Study of JNS024 Extended Release (ER) in Japanese and Korean Patients With Chronic Malignant Tumor-Related Cancer Pain

Pain

Japan, Korea, Republic of
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral Neuropathy

Diabetic Peripheral Neuropathy

United States, Canada, Puerto Rico
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

A Safety and Efficacy Study for Tapentadol (CG5503) Extended Release for Patients With Painful Diabetic Peripheral Neuropathy

Diabetic Neuropathy
Janssen Pharmaceutical K.K.

Completed

A Safety and Efficacy Study of Oral Tapentadol Extended-Release in Japanese Participants

Neoplasms

Japan
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

A Study to Evaluate 90-Day Safety of Tapentadol(CG5503) Immediate Release (IR) or Oxycodone Immediate Release in Patients With Chronic Pain

Osteoarthritis | Arthralgia | Low Back Pain | Sciatica | Pain Intensity Assessment
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Terminated

A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)

Diabetic Neuropathy, Painful | Diabetic Polyneuropathy

United States
Grünenthal GmbH

Completed

Effect of a Multiple-dose Oral Administration of CG5503 PR on the Electrical Activity of the Heart in 48 Healthy Men and Women

Prolonged QTc Interval | Pharmacokinetic

Germany
Grünenthal GmbH

Completed

Pharmacokinetic Characterization of Two Novel CG5503 Tablet Formulations in Healthy Volunteers

Pharmacokinetics

Germany
Grünenthal GmbH
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

A Study to Evaluate the Efficacy and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain After Abdominal Hysterectomy

Hysterectomy | Postoperative

Russian Federation, Hungary, Latvia, Poland, Romania, Serbia, Slovakia, Slovenia, Ukraine
Janssen Research & Development, LLC

Completed

A Study of Tapentadol Immediate-Release in the Treatment of Patients With Acute Pain From Bunionectomy

Hallux Valgus

Korea, Republic of
Grünenthal GmbH
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

Pain | Knee Osteoarthritis

Austria, Croatia, Germany, Hungary, Italy, Latvia, Netherlands, Poland, Portugal, Romania, Slovakia, Spain, United Kingdom
Janssen Pharmaceutical K.K.
Grünenthal GmbH

Completed

Phase 2 Study of Tapentadol Prolonged Release in Cancer Pain Participants

Pain | Cancer

Japan
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Withdrawn

To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS

Multiple Sclerosis | Sperm

United States
Grünenthal GmbH
Depomed

Completed

A Study to Look at Tapentadol Oral Solution in Children and Adolescents in Pain

Acute Pain

United States, Bulgaria, Croatia, Czechia, France, Germany, Hungary, Poland, Spain, United Kingdom
Rhode Island Hospital

Completed

Improving Emotion Regulation Skills Among Adolescents Attempting to Lose Weight

Overweight and Obesity

United States
Anesiva, Inc.

Completed

Prevention of Autogenous Vein Graft Failure in Peripheral Artery Bypass Procedures

Ischemia | Arterial Occlusive Diseases | Peripheral Vascular Diseases | Hyperplasia | Graft Occlusion, Vascular

United States, Canada
Columbia University
Biolase Inc

Active, not recruiting

Peri-implantitis Treatment: Clinical Results of Conventional Treatment vs. the Addition of Biolase

Peri-Implantitis

United States
GC Biopharma Corp

Recruiting

A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj.

Hepatitis B

Korea, Republic of
HealthPartners Institute

Terminated

Outreach-ER: A Dementia Care Intervention Program

Dementia

United States
Grünenthal GmbH

Completed

Comparison of Increasing Doses of Tapentadol Versus a Combination of Tapentadol and Pregabalin

Low Back Pain | Neuropathic Pain

Austria, Belgium, Denmark, Germany, Netherlands, Poland, Spain
TaiRx, Inc.

Completed

Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients

Advanced Cancer

Taiwan
Uppsala University

Recruiting

Emotion Regulation Training for Adolescents With ADHD

ADHD | Emotion Regulation | Attention Deficit Disorder With Hyperactivity

Sweden
Jewish General Hospital

Recruiting

Emergency Room Visits and Older Patients (ER2) (ER2)

Emergencies | Length of Stay

Canada
Medical University of South Carolina
Georgia State University

Completed

PTSD Treatment and Emotion Regulation Skills Training for Veterans With Military Sexual Trauma (PE+ER) (PE+ER)

Anxiety Disorders | Stress Disorders, Post-Traumatic | Mental Disorder | Traumatic Stress Disorder

United States
Janssen-Cilag International NV
Grünenthal GmbH

Completed

A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy Compared With Placebo

Hallux Valgus

Taiwan
Aretaieion University Hospital

Recruiting

Tapentadol Versus Tramadol Analgesia Post Cardiac Surgery (vasso-annie)

Pain, Postoperative | Postoperative Pain | Analgesia | Surgery | Pain, Acute | Pain, Procedural | Pain, Chronic | Pain, Neuropathic

Greece
Asieris Pharmaceuticals (AUS) Pty Ltd.

Completed

A Phase I, Two-phase, Crossover Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APL-1501 ER Tablets

Bladder Cancer

Australia
Member Companies of the Opioid PMR Consortium

Terminated

Discontinuation vs Continuation of Long-term Opioid Therapy in Suboptimal and Optimal Responders With Chronic Pain

Opioid-Related Disorders | Drug Abuse | Opiate Addiction | Narcotic Abuse

United States
Washington State University
American Society for Pain Management Nursing

Recruiting

Empowered Relief Delivered by Nurses (ERA)

Pain, Chronic

United States
National Institute of Mental Health (NIMH)

Completed

Assessment of [11C]ER176 to Image Translocator Protein in Brain and Whole Body of Healthy People

Pharmacokinetics | Adult

United States
Korea University Anam Hospital

Completed

YSGG Application in Periodontal Treatment

Periodontal Diseases

Korea, Republic of
Lotus Pharmaceutical

Completed

Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine

Migraine Without Aura | Migraine With Aura

Taiwan
Kowa Research Institute, Inc.

Completed

Study to Investigate the Efficacy and Pharmacokinetic Profile of K-877-ER Compared to K-877-IR

Dyslipidemia

United States
AstraZeneca

Withdrawn

A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects

Healthy Male Subjects | Pharmacokinetics | Safety | Food Effect

United Kingdom

Search clinical trials for: Tapentadol (CG5503) ER

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations